Praxis Precision Medicines Inc. (PRAX)

Overview

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders characterized by an imbalance in neuronal excitation and inhibition. Based in Boston, Massachusetts, and incorporated in 2015, Praxis is committed to addressing the needs of patients with neurological conditions that are often underserved by current treatments. Through its robust pipeline of small molecule and antisense oligonucleotide (ASO) therapies, Praxis aims to target the underlying causes of these disorders. The company's approach involves strategic collaborations and license agreements with industry leaders like RogCon Inc., Ionis Pharmaceuticals, Inc., UCB Biopharma SRL, and The Florey Institute, bolstering its R&D capabilities and expanding its reach in the quest to develop groundbreaking therapies.

Products and Services

• Ulixacaltamide - A small molecule inhibitor of T-type calcium channels, currently in a Phase III clinical trial for treating essential tremor.

This represents Praxis Precision Medicines, Inc.'s forefront in their development pipeline, aiming to address the significant unmet medical need in the management of essential tremor, a common and debilitating movement disorder.

• PRAX-562 - Intended for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE).

This innovative therapy is part of Praxis's commitment to combating severe neurological disorders in children, particularly those affected by DEE, a group of rare epilepsy syndromes that cause developmental impairments.

• PRAX-628 - A developmental drug aimed at treating focal epilepsy.

With PRAX-628, Praxis Precision Medicines, Inc. seeks to advance the treatment landscape for patients suffering from focal epilepsy, which accounts for a significant proportion of all epilepsy cases.

• PRAX-222 - Focused on the treatment of pediatric patients with early-onset SCN2A-DEE.

Targeting a specific genetic disorder, PRAX-222 exemplifies Praxis's precision medicine approach, aiming at therapies that are genetically and mechanistically tailored to individual conditions.

• PRAX-020 - Designed to treat KCNT1 related epilepsies.

This program addresses rare, genetic forms of epilepsy associated with the KCNT1 gene, underlining the company's focus on addressing the underlying genetics of epileptic disorders.

• PRAX-080 - For the treatment of PCDH19.

By developing PRAX-080, Praxis endeavors to provide targeted therapy for PCDH19, a genetic epilepsy syndrome affecting mainly females, marking a step forward in gender-specific treatment development.

• PRAX-090 and PRAX-100 - Aimed at treating SYNGAP1 and SCN2A-LoF, respectively.

These programs highlight Praxis's ongoing efforts to delve into genetically defined disorders, offering hope for patients with SYNGAP1 and SCN2A loss of function mutations through novel therapeutic approaches.